What "off-label" prescribing means

“Off-label” is one of those terms that sounds more alarming than it is. The word “label” makes it sound like something is being done outside the rules. In practice, it’s a long-standing and legitimate part of medical practice in Australia — and understanding what it actually means helps you read clinical conversations more accurately.

The short version

A medicine in Australia is approved by the TGA for specific uses — called indications — based on the clinical data submitted by the sponsor at the time of approval. These approved uses are described in the medicine’s official product information. Anything within those approved uses is on-label.

Off-label prescribing is when a prescriber prescribes the medicine for a use that isn’t covered by the official product information. That could mean:

• A condition the medicine wasn’t approved for
• A dose outside the approved range
• A different age group (often children, where many medicines lack paediatric approval)
• A different route of administration

The medicine itself is the same registered, ARTG-listed, regulated product. The off-label part refers to the specific use the prescriber is recommending.

Why off-label prescribing exists

Off-label prescribing happens for several reasonable reasons.

Evidence moves faster than regulatory approvals. A medicine might be approved for one use, and over years of clinical practice and research, evidence accumulates that it’s also useful for another condition. Updating the official indications requires the sponsor to submit additional data to the TGA, which costs time and money. Until that happens, the medicine is used off-label for the new indication, supported by the evidence base in the medical literature and professional guidelines.

Some patient groups are under-represented in clinical trials. Children, pregnant women, older adults and people with complex comorbidities are often excluded from the trials used for initial regulatory approval. This means medicines may be approved for “adults” in a general sense but lack specific paediatric or other approvals — even though clinical practice has long supported their use in those groups.

Some sponsors don’t pursue every approval. Updating the indications of a medicine costs the sponsor money. If the commercial return doesn’t justify the regulatory work — for example, an old medicine that’s now off-patent — the sponsor may never apply to extend the indications, even when the medicine is widely used for the broader purpose.

Clinical judgement sometimes leads outside the published indications. A patient’s specific situation may not fit neatly into the approved indications, and the prescriber may judge that the medicine is the best option based on the full clinical picture. That’s part of what medical training is for.

In Australia, off-label prescribing is widely accepted as a legitimate part of medical practice — supported by the Royal Australian College of General Practitioners, specialty colleges, and the Medical Board. It comes with specific professional responsibilities for the prescriber (covered below).

What the prescriber is supposed to do

Off-label prescribing isn’t a free-for-all. There’s professional guidance — from the Medical Board, RACGP and other bodies — about what a prescriber should do when using a medicine off-label.

The expectations typically include:

• Having a clear clinical rationale for the off-label use, based on available evidence and professional guidance
• Discussing the off-label nature of the use with the patient — not as a footnote, but as part of the conversation about options
• Discussing the alternatives, including approved alternatives if they exist
• Discussing the implications — including cost (often not PBS-subsidised), monitoring requirements, and what to look out for
• Documenting the rationale in the patient’s record
• Taking responsibility for the clinical decision, including ongoing review

In practice, this means a thoughtful off-label conversation looks a lot like any other clinical decision-making conversation: “Here’s what I think might help. Here’s why I think that. Here are the alternatives. Here’s what we’ll do to monitor it. Here are the practical implications. Any questions?”

Implications for patients

A few practical things flow from off-label prescribing.

Cost. Off-label prescriptions are usually not PBS-subsidised, since PBS listings are indication-specific. The patient typically pays the private price set by the pharmacy, which is often higher than the PBS co-payment. The prescriber should mention this — if they haven’t, it’s reasonable to ask before filling the script.

Monitoring. Some off-label uses involve different monitoring than the approved use — different blood tests, different review intervals, or different things to watch for. The prescriber should explain what monitoring they’re recommending and why.

Insurance and travel. Some private health insurance, travel insurance and similar products have specific clauses around prescription medicines. Off-label use can occasionally create complications. For long-term off-label prescriptions, a quick check with your insurer is sometimes worthwhile.

Records. Make sure your full medication list — including off-label prescriptions — is shared with any other health professional you see. The off-label part isn’t always obvious from the medicine name alone, and the broader clinical picture matters.

Questions worth asking

If a prescriber suggests an off-label use, a few questions help you understand the recommendation:

• “What’s the evidence base for using this medicine in this way?”
• “What are the alternative approaches, including on-label ones?”
• “Why is this option preferable in my situation?”
• “What should we be monitoring, and how often?”
• “What signs would tell us it’s working, and what signs would tell us to change course?”
• “What does this mean for cost?”
• “What should I tell my pharmacist?”

A good prescriber will welcome these questions — they’re exactly the conversation that the professional guidance expects to happen.

Off-label vs unregulated

It’s worth being clear about what off-label is not.

Off-label is not the same as using an unregistered medicine. Off-label use involves a medicine that’s properly registered on the ARTG and available through normal channels — it’s just being prescribed for a different use than the registered indications.

Off-label is not the same as compounding. Compounded medicines are individually made up by a compounding pharmacy for a specific patient. That’s a separate regulatory pathway with its own rules.

Off-label is not the same as unsupervised use. Off-label use sits within the prescriber–patient relationship and the supply pathway, just like any other prescription.

Off-label is not the same as experimental. Most off-label use involves established medicines with established safety profiles, used in ways supported by the broader literature.

The everyday reality

For many adults on long-term medications, at least one of their prescriptions is likely to be at least partially off-label in some respect — different dose, different combination, different indication. This is normal in modern clinical practice and reflects the gap between what clinical evidence supports and what the regulatory indications cover.

The point of understanding off-label prescribing isn’t to be wary of it — it’s to be informed about it. A good prescriber will explain when they’re going off-label, why they think it makes sense, and what it means for you. Knowing the term means you can engage with that conversation rather than being lost in the language.

It’s also a useful reminder that medicines are tools, regulated for safety but applied by clinicians using judgement. The label tells you what the tool is officially for. The clinical conversation is about whether it’s the right tool for your situation.